MarketPulse

regulatory approvals

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Gene Therapy's Hidden Engine: AAV Vector Market Poised to Explode 22% Annually Through 2034

AAV vector manufacturing market to surge from $874M (2025) to $5.2B (2034) as gene therapy breakthroughs drive demand for specialized production infrastructure.
TMOCRLLZAGYgene therapybiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Bispecific Antibodies Poised for $60B Market by 2031 as 550+ Trials Reshape Therapeutics

Bispecific antibody market projected to reach $60 billion by 2031 from $16 billion in 2025, with 550+ clinical trials and 18 approved drugs driving sector transformation.
AMGNJNJPFEABBVRHHBY+3clinical trialsautoimmune diseases
BenzingaBenzinga··Vandana Singh

ImmunityBio Surges on Strong Q1 Revenue, But FDA Warning Clouds Outlook

ImmunityBio stock rallied 7% after reporting $44.2M in Q1 product revenue, up 168% YoY, despite FDA warning over Anktiva marketing claims.
IBRXAnktivaImmunityBio
Investing.comInvesting.com··Gurufocus

Viatris Stock Trading Below Fair Value With 13.5% FCF Yield and Growth Catalysts Ahead

Viatris trades 17% below peers despite 13.5% FCF yield and $2.2B annual cash generation. Growth catalysts and cost-savings program launching 2026 suggest significant upside.
VTRSTEVAshare buybacksEBITDA growth
GlobeNewswire Inc.GlobeNewswire Inc.··Na

XOMA Royalty Surges on 68% Royalty Growth and Aggressive Portfolio Expansion

XOMA Royalty reports $50M+ cash receipts in 2025, with royalties up 68% YoY. Company adds 22 assets, completes seven acquisitions, and repurchases $16M in shares.
DAWNRZLTGOSSZVRAMIRM+3acquisitionsshare buyback